{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:33:50Z","timestamp":1790483630670,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Government of India Department of Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020582","name":"National Institute of Pharmaceutical Education and Research, Raebareli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.arr.2022.101816","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:48:22Z","timestamp":1670273302000},"page":"101816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics"],"prefix":"10.1016","volume":"84","author":[{"given":"Amrita","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumari","family":"Preeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamatham Pushpa","family":"Tryphena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Bala","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmendra Kumar","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2022.101816_bib1","first-page":"S183","article-title":"Gene therapy for Parkinson\u2019s disease associated with GBA1 mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib2","first-page":"2","article-title":"SCARB2 variants and glucocerebrosidase activity in Parkinson\u2019s disease","author":"Alcalay","year":"2016","journal-title":"npj Park. Dis"},{"key":"10.1016\/j.arr.2022.101816_bib3","doi-asserted-by":"crossref","first-page":"E4688","DOI":"10.1073\/pnas.1523597113","article-title":"Deubiquitinase Usp8 regulates \u03b1-synuclein clearance and modifies its toxicity in Lewy body disease","volume":"113","author":"Alexopoulou","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.arr.2022.101816_bib4","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archneurol.2010.198","article-title":"Chaperone-mediated autophagy markers in Parkinson disease brains","volume":"67","author":"Alvarez-Erviti","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2013.73","article-title":"Influence of microRNA deregulation on chaperone-mediated autophagy and \u03b1-synuclein pathology in parkinson\u2019s disease","volume":"4","author":"Alvarez-Erviti","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.arr.2022.101816_bib6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s13311-013-0211-8","article-title":"Epigenetic landscape of parkinson\u2019s disease: emerging role in disease mechanisms and therapeutic modalities","volume":"10","author":"Ammal Kaidery","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2022.101816_bib7","doi-asserted-by":"crossref","unstructured":"Angelopoulou, E., Paudel, Y.N., Piperi, C., 2019. miR-124 and Parkinson\u2019s disease: A biomarker with therapeutic potential, Pharmacological Research. Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.phrs.2019.104515.","DOI":"10.1016\/j.phrs.2019.104515"},{"key":"10.1016\/j.arr.2022.101816_bib8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00018-020-03673-x","article-title":"Emerging role of S100B protein implication in Parkinson\u2019s disease pathogenesis","volume":"78","author":"Angelopoulou","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.arr.2022.101816_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08324-z","article-title":"The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress \u03b1-synuclein aggregation","volume":"7","author":"Aprile","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-50256-3","article-title":"Expression profiling of blood microRNAs 885, 361, and 17 in the patients with the Parkinson\u2019s disease: integrating interaction data to uncover the possible triggering age-related mechanisms","volume":"9","author":"Behbahanipour","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00226-x","article-title":"Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review","volume":"10","author":"Behl","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2022.101816_bib12","first-page":"12","article-title":"Expanding the role of proteasome homeostasis in Parkinson\u2019s disease: beyond protein breakdown","author":"Bi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.arr.2022.101816_bib13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1353-8020(11)70004-9","article-title":"Autosomal recessive parkinsonism","volume":"18","author":"Bonifati","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib14","first-page":"123","article-title":"NEAT1 on the field of Parkinson\u2019s disease: offense, defense, or a player on the bench?","volume":"11","author":"Boros","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/jnr.23377","article-title":"Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson\u2019s disease","volume":"92","author":"Botta-Orfila","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.arr.2022.101816_bib16","first-page":"589","article-title":"C-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib17","first-page":"18","article-title":"Parkinson\u2019s disease: from pathogenesis to pharmacogenomics","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2022.101816_bib18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1055\/a-1013-7686","article-title":"Pharmacogenetics of atremorine-induced neuroprotection and dopamine response in Parkinson\u2019s disease","volume":"85","author":"Cacabelos","year":"2019","journal-title":"Planta Med."},{"key":"10.1016\/j.arr.2022.101816_bib19","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/med.21838","article-title":"Atremorine in Parkinson\u2019s disease: from dopaminergic neuroprotection to pharmacogenomics","volume":"41","author":"Cacabelos","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.arr.2022.101816_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1471-4159.2009.06191.x","article-title":"Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson\u2019s disease pathogenesis","volume":"110","author":"Chau","year":"2009","journal-title":"J. Neurochem"},{"key":"10.1016\/j.arr.2022.101816_bib21","first-page":"10","article-title":"Blood neurofilament light chain in parkinson\u2019s disease: Comparability between parkinson\u2019s progression markers initiative (ppmi) and asian cohorts","author":"Chen","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.arr.2022.101816_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.941","article-title":"Identification of aberrant circulating miRNAs in Parkinson\u2019s disease plasma samples","volume":"8","author":"Chen","year":"2018","journal-title":"Brain Behav."},{"key":"10.1016\/j.arr.2022.101816_bib23","article-title":"The potential effects of oxidative stress-related plasma abnormal protein aggregate levels on brain volume and its neuropsychiatric consequences in Parkinson\u2019s disease","volume":"2021","author":"Chen","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.arr.2022.101816_bib24","first-page":"1","article-title":"Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson\u2019s disease","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mds.27693","article-title":"LRP10 in autosomal-dominant Parkinson\u2019s disease","volume":"34","author":"Chen","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib26","doi-asserted-by":"crossref","first-page":"54215","DOI":"10.18632\/oncotarget.11090","article-title":"Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson\u2019s disease","volume":"7","author":"Chiu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.arr.2022.101816_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/labinvest.2013.60","article-title":"Elevated TRAF2\/6 expression in Parkinson\u2019s disease is caused by the loss of Parkin E3 ligase activity","volume":"93","author":"Chung","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.arr.2022.101816_bib28","first-page":"13","article-title":"The Role of NEDD4 E3 ubiquitin\u2013protein ligases in Parkinson\u2019s disease","author":"Conway","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.arr.2022.101816_bib29","first-page":"1606","article-title":"ARTICLE DNA methylation of the MAPT gene in Parkinson\u2019s disease cohorts and modulation by Vitamin E","volume":"29","author":"Coupland","year":"2014","journal-title":"Vitro"},{"key":"10.1016\/j.arr.2022.101816_bib30","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/cdd.2014.179","article-title":"GSK-3\u03b2 dysregulation contributes to parkinson\u2019s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and \u03b1-synuclein","volume":"22","author":"Credle","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.arr.2022.101816_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.nbd.2015.02.005","article-title":"\u03b1-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson\u2019s disease","volume":"76","author":"Credle","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biocel.2005.09.018","article-title":"Coordination of ER and oxidative stress signaling: the PERK\/Nrf2 signaling pathway","volume":"38","author":"Cullinan","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.arr.2022.101816_bib33","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.jmb.2020.02.033","article-title":"Impairment of lysosome function and autophagy in rare neurodegenerative diseases","volume":"432","author":"Darios","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.arr.2022.101816_bib34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ana.20831","article-title":"Early-onset familial parkinsonism due to POLG mutations","volume":"59","author":"Davidzon","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib35","first-page":"12","article-title":"The genetics of parkinson\u2019s disease and implications for clinical practice","author":"Day","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.arr.2022.101816_bib36","first-page":"461","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.arr.2022.101816_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/1354750X.2015.1118544","article-title":"A panel of four decreased serum microRNAs as a novel biomarker for early Parkinsons disease","volume":"21","author":"Dong","year":"2016","journal-title":"Biomarkers"},{"key":"10.1016\/j.arr.2022.101816_bib39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4103\/1673-5374.300980","article-title":"Oxidative stress factors in Parkinson\u2019s disease","volume":"16","author":"Dorszewska","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.arr.2022.101816_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12640-009-9094-1","article-title":"Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue","volume":"17","author":"Dyllick-Brenzinger","year":"2010","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.arr.2022.101816_bib41","first-page":"299","article-title":"Molecular chaperones in Parkinson\u2019s disease - Present And future","volume":"1","author":"Ebrahimi-Fakhari","year":"2011","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-319-11731-7_11","article-title":"CHIP: A Co-chaperone for degradation by the proteasome","volume":"78","author":"Edkins","year":"2015","journal-title":"Subcell. Biochem"},{"issue":"11","key":"10.1016\/j.arr.2022.101816_bib43","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/genes12111681","article-title":"Mapping the Diverse and Inclusive Future of Parkinson\u2019s Disease Genetics and Its Widespread Impact","volume":"12","author":"Elsayed","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.arr.2022.101816_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2021.05.014","article-title":"ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson\u2019s disease","volume":"88","author":"Fern\u00e1ndez-Espejo","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.parkreldis.2018.06.004","article-title":"DNAJC13 mutation screening in patients with Parkinson\u2019s disease from South Italy","volume":"55","author":"Gagliardi","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib46","first-page":"12","article-title":"Epigenetic inactivation of the autophagy\u2013lysosomal system in appendix in Parkinson\u2019s disease","author":"Gordevicius","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2022.101816_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrn3427","article-title":"Histone acetylation: molecular mnemonics on the chromatin","volume":"14","author":"Gr\u00e4ff","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.neurobiolaging.2021.08.013","article-title":"Enrichment of rare variants in E3 ubiquitin ligase genes in Early onset Parkinson\u2019s disease","volume":"109","author":"Gu","year":"2022","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2022.101816_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.202012188","article-title":"Targeted attenuation of elevated histone marks at SNCA alleviates \u03b1\u2010synuclein in Parkinson\u2019s disease","volume":"13","author":"Guhathakurta","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2022.101816_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100087","article-title":"GSK2606414 attenuates PERK\/p-eIF2\u03b1\/ATF4\/CHOP axis and augments mitochondrial function to mitigate high glucose induced neurotoxicity in N2A cells","volume":"3","author":"Gundu","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.arr.2022.101816_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2013.05.010","article-title":"Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson\u2019s disease","volume":"140","author":"Harrison","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.arr.2022.101816_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.arr.2022.101816_bib53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","article-title":"ER stress and the unfolded protein response in neurodegeneration","volume":"13","author":"Hetz","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.arr.2022.101816_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000324514","article-title":"Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson\u2019s disease","volume":"8","author":"Hinault","year":"2011","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib56","doi-asserted-by":"crossref","unstructured":"Hai, T., Lu, D., Wolford, C.C., 2006. Transcription factors \/ atf. Encyclopedia of Respiratory Medicine, Academic Press, Pages 257-260.https:\/\/doi.org\/10.1016\/B0-12-370879-6\/00388-4.","DOI":"10.1016\/B0-12-370879-6\/00388-4"},{"key":"10.1016\/j.arr.2022.101816_bib57","doi-asserted-by":"crossref","unstructured":"Hommen, F., Bilican, S., Vilchez, D., 2022. Protein clearance strategies for disease intervention, Journal of Neural Transmission. Springer Vienna. https:\/\/doi.org\/10.1007\/s00702\u2013021-02431-y.","DOI":"10.1007\/s00702-021-02431-y"},{"key":"10.1016\/j.arr.2022.101816_bib58","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mds.25349","article-title":"The role of SCARB2 as susceptibility factor in Parkinson\u2019s disease","volume":"28","author":"Hopfner","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105527","article-title":"Molecular chaperones and Parkinson\u2019s disease","volume":"160","author":"Hu","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib60","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.18632\/aging.202389","article-title":"CHIP protects against MPP+\/MPTP-induced damage by regulating Drp1 in two models of Parkinson\u2019s disease","volume":"13","author":"Hu","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.arr.2022.101816_bib61","first-page":"S117","article-title":"Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a\u00a0GBA\u00a0mutation","volume":"126","author":"Judith Peterschmitt","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.arr.2022.101816_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2014.00049","article-title":"Epigenetics across the human lifespan","volume":"2","author":"Kanherkar","year":"2014","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.arr.2022.101816_bib63","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1074\/mcp.RA120.002055","article-title":"Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson\u2019s disease","volume":"19","author":"Karayel","year":"2020","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.arr.2022.101816_bib64","article-title":"Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders","volume":"2","author":"Khatri","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Disco"},{"key":"10.1016\/j.arr.2022.101816_bib65","first-page":"1","article-title":"Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson\u2019s disease","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101618","article-title":"Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson\u2019s disease","volume":"78","author":"Kip","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2022.101816_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological \u03b1-synuclein in blood","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.arr.2022.101816_bib68","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/mds.28605","article-title":"Dysfunction of RAB39B-mediated vesicular trafficking in lewy body diseases","volume":"36","author":"Koss","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib69","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1007\/s12035-018-1334-z","article-title":"Cellular proteostasis in neurodegeneration","volume":"56","author":"Kurtishi","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2022.101816_bib70","doi-asserted-by":"crossref","unstructured":"Kurup, P.K., Xu, J., Videira, R.A., Ononenyi, C., Baltazar, G., Lombroso, P.J., Nairn, A.C., 2015. STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson\u2019s disease. Proc. Natl. Acad. Sci. U. S. A. 112, 1202\u20131207. https:\/\/doi.org\/10.1073\/pnas.1417423112.","DOI":"10.1073\/pnas.1417423112"},{"key":"10.1016\/j.arr.2022.101816_bib71","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0006-291X(02)02228-3","article-title":"Characterization of the novel human transmembrane protein 9 (TMEM9) that localizes to lysosomes and late endosomes","volume":"297","author":"Kveine","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2022.101816_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00401-016-1590-9","article-title":"Epigenetic regulation in Parkinson\u2019s disease","volume":"132","author":"Labb\u00e9","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2022.101816_bib73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41418-020-00667-x","article-title":"Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective","volume":"28","author":"Le Guerrou\u00e9","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.arr.2022.101816_bib74","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2022.101816_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/EBC20160025","article-title":"Epigenetic inheritance of proteostasis and ageing","volume":"60","author":"Li","year":"2016","journal-title":"Essays Biochem"},{"key":"10.1016\/j.arr.2022.101816_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2021.700959","article-title":"Serum miR-214 serves as a biomarker for prodromal Parkinson\u2019s disease","volume":"13","author":"Li","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib77","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.14336\/AD.2020.0216","article-title":"The critical role of SIRT1 in Parkinson\u2019s disease: mechanism and therapeutic considerations","volume":"11","author":"Li","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.arr.2022.101816_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep00954","article-title":"DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease","volume":"2","author":"Lin","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib79","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1523\/JNEUROSCI.2600-15.2015","article-title":"Chaperones in neurodegeneration","volume":"35","author":"Lindberg","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib80","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41380-021-01233-8","article-title":"Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases","volume":"27","author":"Liu","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2022.101816_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100972","article-title":"Neuronal autophagy and mitophagy in Parkinson\u2019s disease","volume":"82","author":"Lizama","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.arr.2022.101816_bib82","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/00207454.2019.1681422","article-title":"Novel POLG mutation in a patient with early-onset parkinsonism, progressive external ophthalmoplegia and optic atrophy","volume":"130","author":"Ma","year":"2020","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jchemneu.2003.08.007","article-title":"ER chaperone functions during normal and stress conditions","volume":"28","author":"Ma","year":"2004","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.arr.2022.101816_bib84","doi-asserted-by":"crossref","first-page":"16275","DOI":"10.3390\/ijms160716275","article-title":"Experimental evidence shows salubrinal, an eIF2\u03b1 dephosphorylation inhibitor, reduces xenotoxicant-induced cellular damage","volume":"16","author":"Matsuoka","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2022.101816_bib85","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbrc.2020.06.155","article-title":"Cathepsin K is a potent disaggregase of \u03b1-synuclein fibrils","volume":"529","author":"McGlinchey","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2022.101816_bib86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2012.06.031","article-title":"HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers","volume":"150","author":"Mendillo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.arr.2022.101816_bib87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.brainres.2016.04.042","article-title":"ER stress and Parkinson\u2019s disease: pathological inputs that converge into the secretory pathway","volume":"1648","author":"Mercado","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2022.101816_bib88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2018.01.004","article-title":"Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson\u2019s disease","volume":"112","author":"Mercado","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neulet.2017.02.027","article-title":"PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson\u2019s disease","volume":"645","author":"Miki","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2022.101816_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2017.00225","article-title":"Implications of DNA methylation in Parkinson\u2019s disease","volume":"10","author":"Miranda-Morales","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib91","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1074\/jbc.TM117.000893","article-title":"Mitochondrial proteostasis in the context of cellular and organismal health and aging","volume":"294","author":"Moehle","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2022.101816_bib92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib93","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1083\/jcb.153.5.1011","article-title":"Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2\u03b1","volume":"153","author":"Novoa","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.arr.2022.101816_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105482","article-title":"Parkinson\u2019s disease risk genes act in glia to control neuronal \u03b1-synuclein toxicity","volume":"159","author":"Olsen","year":"2021","journal-title":"Neurobiol. Dis."},{"issue":"187","key":"10.1016\/j.arr.2022.101816_bib95","article-title":"Sequencing of the GBA co-activator, Saposin C, in Parkinson disease","volume":"72","author":"Ouled Amar Bencheikh","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2022.101816_bib96","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.cdd.4401373","article-title":"Roles of CHOP\/GADD153 in endoplasmic reticulum stress","volume":"11","author":"Oyadomari","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.arr.2022.101816_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-022-00281-6","article-title":"LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease","volume":"11","author":"Pang","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2022.101816_bib98","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1021\/acschemneuro.9b00244","article-title":"A cleaning crew: the pursuit of autophagy in Parkinson\u2019s disease","volume":"10","author":"Parekh","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib99","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1074\/jbc.M115.675488","article-title":"Regulation of histone acetylation by autophagy in Parkinson disease","volume":"291","author":"Park","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2022.101816_bib100","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nbt.1685","article-title":"Epigenetic modifications and human disease","volume":"28","author":"Portela","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.arr.2022.101816_bib101","first-page":"1","article-title":"Recombinant pro-CTSD (cathepsin D) enhances SNCA\/\u03b1-Synuclein degradation in \u03b1-Synucleinopathy models","volume":"00","author":"Prieto Huarcaya","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.arr.2022.101816_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.201798099","article-title":"Rab29 activation of the Parkinson\u2019s disease\u2010associated LRRK2 kinase","volume":"37","author":"Purlyte","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.arr.2022.101816_bib103","first-page":"10","article-title":"The unfolded protein response as a guardian of the secretory pathway","author":"Radanovi\u0107","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arr.2022.101816_bib104","doi-asserted-by":"crossref","first-page":"19307","DOI":"10.1002\/jcp.28622","article-title":"Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson\u2019s disease and epigenetic-based therapies","volume":"234","author":"Renani","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.arr.2022.101816_bib105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neurol.2020.07.016","article-title":"Pathophysiology of Parkinson\u2019s disease: Mitochondria, alpha-synuclein and much more","volume":"177","author":"Rouaud","year":"2021","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep30793","article-title":"Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson\u2019s disease patients","volume":"6","author":"Saito","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib107","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/biom5020735","article-title":"Sirtuins and proteolytic systems: implications for pathogenesis of synucleinopathies","volume":"5","author":"Sampaio-Marques","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2022.101816_bib108","first-page":"132","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.11.015","article-title":"Autophagy lysosomal pathway dysfunction in Parkinson\u2019s disease; evidence from human genetics","volume":"73","author":"Senkevich","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00537","article-title":"Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation","volume":"11","author":"Shukla","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.arr.2022.101816_bib111","first-page":"19","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib112","doi-asserted-by":"crossref","unstructured":"Su, X., Chu, Y., Kordower, J.H., Li, B., Cao, H., Huang, L., 2015. PGC \u2212 1 \u03b1 Promoter Methylation in Parkinson \u2019 s Disease 1\u201324. https:\/\/doi.org\/10.1371\/journal.pone.0134087.","DOI":"10.1371\/journal.pone.0134087"},{"key":"10.1016\/j.arr.2022.101816_bib113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.expneurol.2018.01.015","article-title":"Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease","volume":"303","author":"Sun","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib114","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1353-8020(11)70005-0","article-title":"Autosomal dominant Parkinson\u2019s disease","volume":"18","author":"Sundal","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mds.28342","article-title":"Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease","volume":"36","author":"Tan","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2022.101816_bib116","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbamcr.2013.03.012","article-title":"Proteostasis and neurodegeneration: The roles of proteasomal degradation and autophagy","volume":"1843","author":"Tanaka","year":"2014","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res"},{"key":"10.1016\/j.arr.2022.101816_bib117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nbd.2010.01.007","article-title":"TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson\u2019s disease and dementia with Lewy bodies","volume":"38","author":"Tanji","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101816_bib118","first-page":"441","article-title":"MiRNA\u2011384\u20135p regulates the progression of Parkinson\u2019s disease by targeting SIRT1 in mice and SH\u2011SY5Y cells","volume":"45","author":"Tao","year":"2020","journal-title":"Int. J. Mol. Med"},{"key":"10.1016\/j.arr.2022.101816_bib119","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.molmed.2020.07.004","article-title":"Pro-cathepsin D, prosaposin, and progranulin: lysosomal networks in Parkinsonism","volume":"26","author":"Tayebi","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.arr.2022.101816_bib120","doi-asserted-by":"crossref","unstructured":"Teske, B.F., Baird, T.D., Wek, R.C., 2011. Methods for analyzing eIF2 kinases and translational control in the unfolded protein response, 1st ed, Methods in Enzymology. Elsevier Inc. https:\/\/doi.org\/10.1016\/B978\u20130-12\u2013385114-7.00019\u20132.","DOI":"10.1016\/B978-0-12-385114-7.00019-2"},{"key":"10.1016\/j.arr.2022.101816_bib121","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acn3.50990","article-title":"Nonmercaptalbumin as an oxidative stress marker in Parkinson\u2019s and PARK2 disease","volume":"7","author":"Ueno","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib122","doi-asserted-by":"crossref","unstructured":"Vastrad, B., Vastrad, C., Nilaya, C., 2022. Bioinformatics and next generation sequencing data analysis to identify key genes and pathways influencing in Parkinson\u2019s disease. bioRxiv 2022.02.27.482208.","DOI":"10.1101\/2022.02.27.482208"},{"key":"10.1016\/j.arr.2022.101816_bib123","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/hmg\/ddt570","article-title":"DNAJC13 mutations in Parkinson disease","volume":"23","author":"Vilari\u00f1o-G\u00fcell","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2022.101816_bib124","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2022.101816_bib125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","article-title":"The Lewy body in Parkinson\u2019s disease: molecules implicated in the formation and degradation of \u03b1-synuclein aggregates","volume":"27","author":"Wakabayashi","year":"2007","journal-title":"Neuropathology"},{"key":"10.1016\/j.arr.2022.101816_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2015.00433","article-title":"Alpha-synuclein toxicity in the early secretory pathway: how it drives neurodegeneration in parkinsons disease","volume":"9","author":"Wang","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib127","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.brainres.2014.01.003","article-title":"Salubrinal protects against rotenone-induced SH-SY5Y cell death via ATF4-parkin pathway","volume":"1549","author":"Wu","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2022.101816_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells8111317","article-title":"Autophagic- and lysosomal-related biomarkers for Parkinson\u2019s disease: lights and shadows","volume":"8","author":"Xicoy","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.arr.2022.101816_bib129","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1172\/JCI37617","article-title":"Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation","volume":"119","author":"Xiong","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2022.101816_bib130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.arr.2022.101816_bib131","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/bi401191v","article-title":"Saposin C protects glucocerebrosidase against \u03b1-synuclein inhibition","volume":"52","author":"Yap","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.arr.2022.101816_bib132","doi-asserted-by":"crossref","unstructured":"Yates, D., 2011. Parkinson disease: New developments in CSF biomarkers for early detection and monitoring of Parkinson disease. https:\/\/doi.org\/10.1002\/ana.22311.","DOI":"10.1038\/nrneurol.2010.184"},{"key":"10.1016\/j.arr.2022.101816_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-05227-6","article-title":"Early downregulation of hsa-miR-144-3p in serum from drug-na\u00efve Parkinson\u2019s disease patients","volume":"12","author":"Zago","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2022.101816_bib134","first-page":"1","article-title":"MiR-30c-5p\/ATG5 axis regulates the progression of Parkinson\u2019s disease","volume":"15","author":"Zhang","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib135","first-page":"15","article-title":"MiR-30c-5p\/ATG5 axis regulates the progression of Parkinson\u2019s disease","author":"Zhang","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2017.00170","article-title":"Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for Parkinson\u2019s disease","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib137","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.arr.2022.101816_bib138","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s12035-016-9743-3","article-title":"Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson\u2019s Disease","volume":"54","author":"Zhao","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2022.101816_bib139","article-title":"PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease and the global PD","volume":"2","author":"Zheng","year":"2011","journal-title":"Gene Expr. GPEX Consort."},{"key":"10.1016\/j.arr.2022.101816_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2016.00303","article-title":"Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases","volume":"8","author":"Zheng","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2022.101816_bib141","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.arr.2022.101816_bib142","first-page":"1","article-title":"Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson\u2019s disease","volume":"81","author":"Zhou","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2022.101816_bib143","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s10072-020-04711-z","article-title":"Reduced serum SIRT1 levels in patients with Parkinson\u2019s disease: a cross-sectional study in China","volume":"42","author":"Zhu","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.arr.2022.101816_bib144","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1046\/j.1471-4159.2003.02273.x","article-title":"HSP27 but not HSP70 has a potent protective effect against \u03b1-synuclein-induced cell death in mammalian neuronal cells","volume":"88","author":"Zourlidou","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2022.101816_bib145","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1093\/hmg\/ddq290","article-title":"TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson\u2019s disease brains","volume":"19","author":"Zucchelli","year":"2010","journal-title":"Hum. Mol. Genet."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163722002586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163722002586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:05:58Z","timestamp":1761591958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163722002586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":145,"alternative-id":["S1568163722002586"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2022.101816","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2022.101816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101816"}}